Inventor · disambiguated record
G. Michael Wall
Also filed as: WALL G M · WALL G MICHAEL
13 granted patents·28 pending applications·71 citations·filing 2001–2025
89Inventor score
Files withNACUITY PHARMACEUTICALS INC20NOVARTIS AG4ALCON INC3ALCON PHARMACEUTICALS LTD3WALL G MICHAEL2
Top patents by PatentIndex Score
41 records- 0193US7977376B2Olopatadine formulations for topical nasal administrationNOVARTIS AG·Filed 2007·Granted Jul 12, 2011·28 cites·2 claims
- 0292US11548851B2Method for preparation of n-acetyl cysteine amide and derivatives thereofNACUITY PHARMACEUTICALS INC·Filed 2021·Granted Jan 10, 2023·3 cites·17 claims
- 0392US11091433B2Method for preparation of N-acetyl cysteine amide and derivatives thereofNACUITY PHARMACEUTICALS INC·Filed 2020·Granted Aug 17, 2021·4 cites·29 claims
- 0492US8399508B2Olopatadine formulations for topical nasal administrationSINGH ONKAR N·Filed 2011·Granted Mar 19, 2013·26 cites·2 claims
- 0587US10590073B2Method for preparation of N-acetyl cysteine amide and derivatives thereofNACUITY PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·5 cites·25 claims
- 0677US8846650B2Method of treating middle ear infectionsWALL G MICHAEL·Filed 2009·Granted Sep 30, 2014·3 cites·10 claims
- 0775US9345714B2Method of treating middle ear infectionsALCON PHARMACEUTICALS LTD·Filed 2015·Granted May 24, 2016·1 cites·22 claims
- 0875US9149486B2Method of treating middle ear infectionsNOVARTIS AG·Filed 2014·Granted Oct 6, 2015·1 cites·10 claims
- 0968US2024368072A1Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivativesNACUITY PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1066US2024217927A1Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative StressNACUITY PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1165US11753370B2Methods of making deuterium-enriched N-acetylcysteine amide (d-NACA) and (2R, 2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) and using d-NACA and diNACA to treat diseases involving oxidative stressNACUITY PHARMACEUTICALS INC·Filed 2020·Granted Sep 12, 2023·0 cites·7 claims
- 1265US2008214513A1Method of treating middle ear infectionsALCON INC·Filed 2008·Application pending·0 cites
- 1365US2023373913A1Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative StressNACUITY PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1464US2023381120A1Treatment of Age-Related Macular Degeneration, Glaucoma, and Diabetic Retinopathy with N-Acetylcysteine Amide (NACA) or (2R,2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide)(DiNACA)NACUITY PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1563US2024342118A1Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivativesNACUITY PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1662US9402805B1Method of treating middle ear infectionsALCON PHARMACEUTICALS LTD·Filed 2016·Granted Aug 2, 2016·0 cites·22 claims
- 1762US2025352482A1Amorphous dosage form containing ebselenSOUND PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1860US2016361324A1Method of treating middle ear infectionsALCON PHARMACEUTICALS LTD·Filed 2016·Application pending·0 cites
- 1960US2024008971A1Ophthalmic ImplantNACUITY PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2059US2022304955A1Treatment of ferroptosisNACUITY PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2159US2023159448A1Method for Preparation of N-Acetyl Cysteine Amide and Derivatives ThereofNACUITY PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2259US2005059674A1Method of treating middle ear infectionsFiled 2004·Application pending·0 cites
- 2358US12458608B2N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvementNACUITY PHARMACEUTICALS INC·Filed 2020·Granted Nov 4, 2025·0 cites·17 claims
- 2457US12245998B2N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic FibrosisNACUITY PHARMACEUTICALS INC·Filed 2020·Granted Mar 11, 2025·0 cites·15 claims
- 2556US2014227326A1Method of delivering nasal sprayNOVARTIS AG·Filed 2013·Application pending·0 cites
- 2654US2003139382A1Method of treating middle ear infectionsALCON INC·Filed 2002·Application pending·0 cites
- 2752US11766413B2Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)NACUITY PHARMACEUTICALS INC·Filed 2020·Granted Sep 26, 2023·0 cites·17 claims
- 2852US2017172974A1Method of delivering nasal sprayNOVARTIS AG·Filed 2017·Application pending·0 cites
- 2952US2021228509A1Prodrug for the treatment of disease and injury of oxidative stressNACUITY PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3052US2025235416A1Method for preparation of n-acetyl cysteine amide, derivatives and tablets thereofNACUITY PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3151US2021378993A1Treatment of cystinosisNACUITY PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3250US2006110328A1Method of delivering nasal sprayCAGLE GERALD D·Filed 2005·Application pending·0 cites
- 3350US2014007865A1Olopatadine nasal spray regimen for childrenALCON RES LTD·Filed 2013·Application pending·0 cites
- 3450US2019135741A1Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative StressNACUITY PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3548US2004126436A1Compositions for removing human cerumenFiled 2003·Application pending·0 cites
- 3647US2020217852A1Quantitation of Free and Total N-Acetylcysteine Amide and Its Metabolite N-Acetylcysteine in Human Plasma Using Derivatization and Electrospray LC-MS/MSNACUITY PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3745US2004097474A1Use of an anti-allergy agent and a steroid to treat nasal conditionsALCON INC·Filed 2003·Application pending·0 cites
- 3844US2004033208A1Antifungal compositions containing an antibiotic and one or more amidoaminesFiled 2001·Application pending·0 cites
- 3944US2019151271A1Compositions and methods for treatment of eye diseasesUNIV JOHNS HOPKINS·Filed 2018·Application pending·0 cites
- 4038US2011011392A1Olopatadine nasal spray regimen for childrenWALL G MICHAEL·Filed 2010·Application pending·0 cites
- 4129US2012289541A1Methods and compositions for applying moxifloxacin to the earSAWCHUK RONALD J·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when G. Michael Wall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →